Einarsson M, Smedsrød B, Pertoft H
Research Department Biochemistry, KabiVitrum AB, Stockholm, Sweden.
Thromb Haemost. 1988 Jun 16;59(3):474-9.
The mechanism of uptake of tissue plasminogen activator (tPA) in rat liver was studied. Radio-iodinated tPA was removed from the circulation after intravenous administration in a biphasic mode. The initial half life, t1/2(alpha), and the terminal phase, t1/2 (beta), were determined to be 0.5 min and 7.5 min, resp. Separation of the liver cells by collagenase perfusion and density centrifugation, revealed that the uptake per cell was two to three times higher in the non-parenchymal cells than in the parenchymal cells. Endocytosis of fluorescein isothiocyanate-labelled or 125I-labelled tPA was studied in pure cultures of liver cells in vitro. Liver endothelial cells and parenchymal cells took up and degraded tPA. Endocytosis was more efficient in liver endothelial cells than in parenchymal cells, and was almost absent in Kupffer cells. Competitive inhibition experiments showing that excess unlabelled tPA could compete with the uptake and degradation of 125I-tPA, suggested that liver endothelial cells and parenchymal cells interact with the activator in a specific manner. Endocytosis of trace amounts of 125I-tPA in cultures of liver endothelial cells and parenchymal cells was inhibited by 50% in the presence of 19 nM unlabelled tPA. Agents that interfere with one or several steps of the endocytic machinery inhibited uptake and degradation of 125I-tPA in both cell types. These findings suggest that 1) liver endothelial cells and parenchymal cells are responsible for the rapid hepatic clearance of intravenously administered tPA; 2) the activator is taken up in these cells by specific endocytosis, and 3) endocytosed tPA is transported to the lysosomes where it is degraded.
研究了大鼠肝脏摄取组织型纤溶酶原激活剂(tPA)的机制。静脉注射放射性碘化tPA后,其从循环系统中的清除呈双相模式。初始半衰期t1/2(α)和终末相半衰期t1/2 (β)分别确定为0.5分钟和7.5分钟。通过胶原酶灌注和密度离心分离肝细胞,结果显示非实质细胞中每个细胞的摄取量比实质细胞高两到三倍。在体外肝细胞纯培养物中研究了异硫氰酸荧光素标记或125I标记的tPA的内吞作用。肝内皮细胞和实质细胞摄取并降解tPA。肝内皮细胞中的内吞作用比实质细胞更有效,而枯否细胞中几乎不存在内吞作用。竞争性抑制实验表明,过量的未标记tPA可与125I-tPA的摄取和降解竞争,这表明肝内皮细胞和实质细胞以特定方式与激活剂相互作用。在19 nM未标记tPA存在的情况下,肝内皮细胞和实质细胞培养物中微量125I-tPA的内吞作用被抑制了50%。干扰内吞机制一个或多个步骤的试剂抑制了两种细胞类型中125I-tPA的摄取和降解。这些发现表明:1)肝内皮细胞和实质细胞负责静脉注射tPA后肝脏的快速清除;2)激活剂通过特异性内吞作用被这些细胞摄取;3)内吞的tPA被转运到溶酶体中并在那里被降解。